Cholangiocarcinoma Complicating Primary Sclerosing Cholangitis: A 24-Year Experience
Authors:
- G. Morris-StiffGMG. Morris-Stiff
- C. BhatiCBC. Bhati
- S. OlliffSOS. Olliff
- S. HübscherSHS. Hübscher
- B. GunsonBGB. Gunson
- D. MayerDMD. Mayer
- D. MirzaDMD. Mirza
- J. BuckelsJBJ. Buckels
- S.R. BramhallSBS.R. Bramhall
- 29 April 2008
- journal article
- research article
- Published by S. Karger AG in Digestive Surgery
- Vol. 25 (2) , 126-132
Abstract
Aim: To report the prevalence and outcome of cholangiocarcinoma arising in primary sclerosing cholangitis for a British tertiary referral centre. Methods: All patients diagnosed with primary sclerosing cholangitis and concurrent cholangiocarcinoma were identified from a prospectively maintained departmental database, and the mode of presentation, management and outcome were determined. Results: Of 370 patients with primary sclerosing cholangitis, 48 patients (13%) were diagnosed with a cholangiocarcinoma within a median time of 0.51 months (range: 0–73.12) from presentation to the unit. Mode of presentation included: inoperable tumours (n = 14); incidental findings in transplant hepatectomy specimens (n = 13); primary sclerosing cholangitis follow-up (n = 9); transplant work-up (n = 5); transplant waiting list (n = 5); suspected tumour confirmed at transplant (n = 1), and incidental finding at cholecystectomy (n = 1). The diagnosis was confirmed by: radiology-guided biopsy (n = 27); MRI (n = 3); CT (n = 2); laparoscopy or laparotomy (n = 2), and frozen section at transplant (n = 1). Management consisted of: transplantation (n = 14, including 1 abandoned); hepatic resection (n = 8), and palliation through stenting (n = 26). The overall median survival of the cohort was 4.9 months (range: 0.09–104.5). Median survival ranged from 2.6 months (range: 0.09–35.3) for palliation to 7.6 months (range: 0.6–99.6) for transplantation and 52.8 months (range: 3.7–104.5) for resection. There was no difference in survival between the transplant and resection groups (p = 0.14). Conclusions: Cholangiocarcinoma is a common finding in primary sclerosing cholangitis and regular screening of this cohort of patients at referring centres is advocated to detect early tumours, as surgical treatment at an early stage offers significantly better outcomes for this cohort of patients.Keywords
This publication has 18 references indexed in Scilit:
- Oxacillin Resistance of Staphylococcus aureus Isolated from the University Hospital of Botucatu Medical School in BrazilChemotherapy, 2010
- Distribution of staphylococcal cassette chromosome mec (SCCmec) types I, II, III and IV in coagulase-negative staphylococci from patients attending a tertiary hospital in southern BrazilJournal of Medical Microbiology, 2007
- Evaluation of a cefoxitin disk diffusion test for the detection of mecA-positive methicillin-resistant Staphylococcus saprophyticusInternational Journal of Antimicrobial Agents, 2006
- SCCmecin staphylococci: genes on the moveFEMS Immunology & Medical Microbiology, 2006
- Evaluation of phenotypic methods for methicillin resistance characterization in coagulase-negative staphylococci (CNS)Journal of Medical Microbiology, 2004
- Prehospital Delay After Acute Stroke in Kaohsiung, TaiwanStroke, 2004
- Genetic Organization of the Chromosome Region Surrounding mecA in Clinical Staphylococcal Strains: Role of IS 431 -Mediated mecI Deletion in Expression of Resistance in mecA -Carrying, Low-Level Methicillin- Resistant Staphylococcus haemolyticusAntimicrobial Agents and Chemotherapy, 2001
- Antimicrobial Resistance Among Uropathogens that Cause Community‐Acquired Urinary Tract Infections in Women: A Nationwide AnalysisClinical Infectious Diseases, 2001
- Rapid detection of methicillin-resistant Staphylococci by multiplex PCRJournal of Hospital Infection, 1999
- Stroke Patients’ Knowledge of StrokeStroke, 1997